News|Videos|August 14, 2026

How New “Shared Clinical Decision Making” Vaccine Category Will Likely Increase Children’s Disease

In the second part of the interview with Sharon Nachman, MD, she touches upon how the administration’s shared clinical decision-making category related to childhood vaccines will affect the hepatitis B and rotavirus vaccines and the expectations there will be subsequent disease increases.

One of the newer elements within the childhood vaccine schedule is the shared clinical decision-making category. This category was set-up by the leadership of the current Advisory Committee on Immunization Practices (ACIP) and Health and Human Services (HHS) Secretary Robert F. Kennedy as a way to limit childhood vaccines. The vaccine schedule was front and center this week, when President Trump signed an executive order around it, offering directives that mirrored ACIP’s and Kennedy’s wishes.

Related to this article

The Prospective Emergence of XDR Shigella Beyond High-Risk Groups
Los Angeles has been experiencing this challenging bacteria in recent years with the potential of it becoming carbapenem-resistant in the future. Shaun Yang, PhD, D(ABMM), FIDSA, MLS(ASCP), provides commentary about his team's work in this area and the role of genomic sequencing to uncover this troublesome pathogen.
Cefiderocol Continues to Show Activity Against Resistant Gram-Negative Infections
Shionogi data presented at IDWeek 2026 demonstrated a 76.7% clinical response with cefiderocol in carbapenem-resistant respiratory infections and high in vitro activity against resistant P aeruginosa VAP isolates. Christine Slover, PharmD, vice president, Infectious Diseases US Medical Affairs, Shionogi, offers insights on the data as well as clinical considerations for providers when weighing the antibiotic for patients.
Pfizer 25-Valent Pneumococcal Vaccine Boosts Serotype 3 Response in Infants
Alejandra Gurtman, MD, discussed the phase 2 data at IDWeek 2026 which showed the investigational 25-valent pneumococcal conjugate vaccine 25vPnC produced serotype 3 antibody levels about 15-fold higher than Prevnar 20 after the booster dose, targeting a serotype still behind 10.6% of invasive pneumococcal disease in US children younger than five years.